One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Immediate-release source. This page does not provide an extended-release renal regimen. The source dialysis summary is reproduced as listed and is not expanded with unlisted rows.
Both selected tables express total mg/day and print overlapping endpoints at 30 and 60 mL/min. A daily amount is not a per-dose amount.
What to reconcile: Use the indication-specific column, divide as directed, and clarify exact boundary values rather than silently normalizing them.
Open this note and its source referencesUse the indication-specific column and daily total. Printed endpoint overlaps are not silently normalized.
Dialysis evidence: A regimen is reported in selected content
Select the indication-specific normal-renal daily total, then the matching column below; the amounts are total mg/day, not mg/dose.
| CrCl mL/min | Column 1 | Column 2 | Column 3 | Column 4 | Daily frequency |
|---|---|---|---|---|---|
| At least 60 | 150 | 300 | 450 | 600 | 2 or 3 divided doses |
| 30-60 | 75 | 150 | 225 | 300 | 2 or 3 divided doses |
| 15-30 | 25-50 | 75 | 100-150 | 150 | 1 or 2 doses |
| Below 15 | 25 | 25-50 | 50-75 | 75 | Once daily |
Printed overlapping endpoints are retained; exact 30/60 need reconciliation. After each 4-hour HD session, supplement daily dosing: 25 mg/day regimen, add 25-50 mg; 25-50, add 50-75; 50-75, add 75-100; 75, add 100-150. Pediatric renal impairment was not studied. Consider dose-dependent adverse effects; this is not LYRICA CR.
RDM61-official-pregabalin-2b7ae43e92-C1 · Source locator: 2.7 and Table 2
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=pregabalin&s1=RDM61-official-pregabalin-2b7ae43e92&h1=ab10a836c212933a37a241632230e545c467dec8ed0d8a2f22f3ad0d971593ac